Pfizer wins EU label expansion for MenACWY vaccine Nimenrix

Pfizer
Pfizer has won a label expansion in Europe for its MenACWY conjugate vaccine Nimenrix.

More than a year after picking up the shot from GlaxoSmithKline, Pfizer has won a label expansion in Europe for its MenACWY conjugate vaccine Nimenrix. It’s now the only such vaccine available on the continent for those starting at 6 weeks of age.

The new label gives Nimenrix “the broadest age indication of any conjugate vaccine in Europe” against the Neisseria meningitidis serogroups A, C, W-135, and Y, Pfizer Chief Medical and Scientific Affairs Officer Luis Jodar said in a statement.

GSK originally launched Nimenrix back in 2012 for people 1 and older. Now, the first dose can be given after six weeks of age in Europe, with another two months later and a booster dose at 12 months.

Infographic

[Infographic] Machine Learning, Statistics and Optimizing Outcomes

In our infographic, we outline the potential of fusing machine learning and statistics algorithms together to more efficiently analyze clinical trial data output and ultimately revolutionize clinical research.

The label expansion was based off a phase 3 study testing the vaccine in more than 1,000 infants, Pfizer said.

Back in 2015, Glaxo sold the shot—along with another MenACWY vaccine—to Pfizer for $130 million as it worked to close its purchase of Novartis’ stall of vaccines. That transaction boosted GSK to the top of the vaccines world, a position it’s expected to keep through 2022, according to EvaluatePharma.

But as Pfizer experiences a slowdown for its top shot, the pneumococcal disease blocker Prevnar 13, the company has worked to diversify its vaccines offerings through external deals, R&D and M&A. Last week, it backed cancer vax startup Ignite with an option to purchase the company if the work proves promising.

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.